Plateau Mineral Development, Inc (PMDP)
Plateau Mineral Development, Inc. specializes in the exploration and development of gas and oil fields. Currently it is concentrating its efforts in Morgan County, Tennessee. The firm has been in existence for over five years with successful new wells and rework wells selling both gas and oil. In addition to current and future wells, the company is completing its compressor station to sell its gas production more consistently at top market prices through its own tap (the Morgan#4) for direct sales at top market prices. PMD tap (the Morgan #4) is anticipated to connect directly into the twenty-four inch (24”) main east-west SPECTRA (was Duke) pipeline
Etrade Financial ( ETFC )
The value behind E*TRADE FINANCIAL's name lies in its tireless effort to challenge the old ways of doing business. We succeed in delivering a diversified and integrated portfolio of innovative, customer-focused brokerage and banking products and services by remaining true to our operating ideals and well-proven formula-regularly asking, can this be done better? By applying this level of discipline to our Retail, Corporate and Institutional businesses, we are able to deliver long-term value to our customers and to our shareholders.
Mission Statement:
To create long term shareholder value through superior financial performance driven by the delivery of a diversified range of innovative, customer-focused financial products and services and supported by an operating culture based on the highest levels of teamwork, efficiency and integrity.
ARIAD Pharmaceuticals, Inc . ( ARIA )
ARIAD Pharmaceuticals, Inc. engages in the discovery and development of medicines to treat cancers by regulating cell signaling with small molecules in the United States. The company's lead cancer product candidate, AP23573, is an mTOR inhibitor for the treatment of solid tumors, including sarcomas, hormone refractory prostate cancer, endometrial cancer, brain cancer, and leukemias and lymphomas. It studies AP23573 in multiple clinical trials in the U.S. and Europe, and is conducting Phase II clinical trials as a single agent in patients with solid tumors, including sarcomas, hormone refractory prostate cancer, endometrial cancer, brain cancer, and leukemias and lymphomas.